- Home
- IDCC vs GH Comparison
IDCC vs GH Comparison
Compare IDCC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDCC
- GH
- Stock Information
- Founded
- IDCC 1972
- GH 2011
- Country
- IDCC United States
- GH United States
- Employees
- IDCC N/A
- GH N/A
- Industry
- IDCC Multi-Sector Companies
- GH Medical Specialities
- Sector
- IDCC Miscellaneous
- GH Health Care
- Exchange
- IDCC Nasdaq
- GH Nasdaq
- Market Cap
- IDCC 5.6B
- GH 4.9B
- IPO Year
- IDCC N/A
- GH 2018
- Fundamental
- Price
- IDCC $252.80
- GH $41.42
- Analyst Decision
- IDCC Strong Buy
- GH Strong Buy
- Analyst Count
- IDCC 1
- GH 18
- Target Price
- IDCC $160.00
- GH $55.67
- AVG Volume (30 Days)
- IDCC 295.4K
- GH 2.4M
- Earning Date
- IDCC 07-31-2025
- GH 07-30-2025
- Dividend Yield
- IDCC 0.95%
- GH N/A
- EPS Growth
- IDCC 43.26
- GH N/A
- EPS
- IDCC 14.28
- GH N/A
- Revenue
- IDCC $892,584,000.00
- GH $828,849,000.00
- Revenue This Year
- IDCC N/A
- GH $23.36
- Revenue Next Year
- IDCC N/A
- GH $21.43
- P/E Ratio
- IDCC $17.70
- GH N/A
- Revenue Growth
- IDCC 21.83
- GH 28.74
- 52 Week Low
- IDCC $126.43
- GH $20.14
- 52 Week High
- IDCC $277.95
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- IDCC 70.32
- GH 32.00
- Support Level
- IDCC $213.06
- GH $43.25
- Resistance Level
- IDCC $277.95
- GH $46.25
- Average True Range (ATR)
- IDCC 9.12
- GH 1.91
- MACD
- IDCC 2.88
- GH -0.70
- Stochastic Oscillator
- IDCC 61.24
- GH 11.25
About IDCC InterDigital Inc.
InterDigital Inc is a research and development company focused on wireless, video, Artificial Intelligence, and related technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, out of which the majority is from China.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.